上海医药
(601607)
| 流通市值：460.22亿 | | | 总市值：611.88亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 75,261,732,476.16 | 283,579,600,562.98 | 215,072,230,363.46 | 141,592,782,502.79 |
| 营业收入 | 75,261,732,476.16 | 283,579,600,562.98 | 215,072,230,363.46 | 141,592,782,502.79 |
| 二、营业总成本 | 72,826,169,493.52 | 276,283,476,928.98 | 209,405,979,454.06 | 137,611,880,810.19 |
| 营业成本 | 67,168,839,531.08 | 253,163,120,898.92 | 192,652,536,770.53 | 126,660,060,598.69 |
| 税金及附加 | 241,440,476.7 | 854,164,313.59 | 635,973,141.24 | 415,653,784.26 |
| 销售费用 | 3,274,911,800.54 | 13,206,178,224.37 | 9,318,311,278.74 | 6,164,987,968.04 |
| 管理费用 | 1,315,932,843.04 | 5,312,780,131.53 | 4,168,813,594.9 | 2,662,454,335.7 |
| 研发费用 | 468,222,755.7 | 2,340,009,450.65 | 1,515,479,406.31 | 958,949,406.87 |
| 财务费用 | 356,822,086.46 | 1,407,223,909.92 | 1,114,865,262.34 | 749,774,716.63 |
| 其中:利息费用 | 347,642,047.02 | 1,685,890,506.64 | 1,280,705,456.13 | 887,687,766.56 |
| 其中:利息收入 | 38,697,345.58 | -404,967,004.79 | 270,229,488.53 | -176,380,262.05 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 61,408,258.44 | 332,120,868.45 | 113,140,103.93 | 75,751,833.73 |
| 加:投资收益 | -14,115,317.05 | 3,170,143,585.98 | 3,370,051,879.37 | 3,257,333,100.37 |
| 资产处置收益 | 168,790,540.68 | 157,152,717.09 | 160,093,351.68 | 39,986,393.32 |
| 资产减值损失(新) | -72,021,361.87 | -1,018,555,938.73 | -789,412,133.56 | -410,078,463.89 |
| 信用减值损失(新) | -274,438,802.21 | -574,707,845.19 | -624,800,914.09 | -423,970,881.72 |
| 其他收益 | 109,280,290.91 | 579,808,611.17 | 441,446,271.52 | 313,695,950.14 |
| 四、营业利润 | 2,414,466,591.54 | 9,942,085,632.77 | 8,336,769,468.25 | 6,833,619,624.55 |
| 加:营业外收入 | 22,169,942.02 | 105,652,418.79 | 73,319,426.76 | 21,837,269.63 |
| 减:营业外支出 | 17,441,616.13 | 227,933,534.31 | 111,991,782.02 | 34,636,191.45 |
| 五、利润总额 | 2,419,194,917.43 | 9,819,804,517.25 | 8,298,097,112.99 | 6,820,820,702.73 |
| 减:所得税费用 | 569,089,009.98 | 2,846,086,835.76 | 2,311,947,675.2 | 1,826,036,672.44 |
| 六、净利润 | 1,850,105,907.45 | 6,973,717,681.49 | 5,986,149,437.79 | 4,994,784,030.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,850,105,907.45 | 6,973,717,681.49 | 5,986,149,437.79 | 4,994,784,030.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,417,757,054.07 | 5,724,557,508.41 | 5,147,064,933.11 | 4,458,864,876.61 |
| 少数股东损益 | 432,348,853.38 | 1,249,160,173.08 | 839,084,504.68 | 535,919,153.68 |
| 扣除非经常损益后的净利润 | 1,237,778,489.82 | 2,980,440,494.17 | 2,698,865,006.88 | 2,099,764,932.53 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.38 | 1.54 | 1.39 | 1.2 |
| (二)稀释每股收益 | 0.38 | 1.54 | 1.39 | 1.2 |
| 八、其他综合收益 | -16,777,788.77 | 7,600,140.48 | 14,170,692.53 | 19,680,758.31 |
| 归属于母公司股东的其他综合收益 | -18,857,590.56 | 1,308,265.94 | -3,033,432.4 | 4,161,971.75 |
| 九、综合收益总额 | 1,833,328,118.68 | 6,981,317,821.97 | 6,000,320,130.32 | 5,014,464,788.6 |
| 归属于母公司股东的综合收益总额 | 1,398,899,463.51 | 5,725,865,774.35 | 5,144,031,500.71 | 4,463,026,848.36 |
| 归属于少数股东的综合收益总额 | 434,428,655.17 | 1,255,452,047.62 | 856,288,629.61 | 551,437,940.24 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |